{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:49:12Z","timestamp":1774993752441,"version":"3.50.1"},"reference-count":70,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1779,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1111\/j.1365-2362.2010.02399.x","type":"journal-article","created":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T12:51:20Z","timestamp":1287406280000},"page":"334-342","source":"Crossref","is-referenced-by-count":21,"title":["Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach"],"prefix":"10.1111","volume":"41","author":[{"given":"W. Alexander","family":"Mann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,10,18]]},"reference":[{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB1|cit1","first-page":"433","volume-title":"Pituitary","author":"Molitch","year":"1995"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S0140-6736(98)03356-X","article-title":"Growth hormone and prolactin excess","volume":"352","author":"Colao","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross- sectional study in the province of Liege, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1056\/NEJM198101153040306","article-title":"Microadenomas of the pituitary gland and abnormal sellar tomograms in an unselected autopsy series","volume":"304","author":"Burrow","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","article-title":"Age-related and gender-related occurrence of pituitary adenomas","volume":"41","author":"Mindermann","year":"1994","journal-title":"Clin Endocrinol"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1515\/JPEM.2000.13.3.261","article-title":"Peripubertal prolactinomas: clinical presentation and longterm outcome with different therapeutic approaches","volume":"13","author":"Fideleff","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/jc.87.2.457","article-title":"Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study","volume":"87","author":"Verges","year":"2002","journal-title":"J Clin Endo Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/frne.2001.0220","article-title":"Transforming growth factor-beta regulation of estradiol- induced prolactinomas","volume":"22","author":"Hentges","year":"2001","journal-title":"Front Neuroendocrinol"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp025334","article-title":"Clinical practice. Prolactinoma","volume":"349","author":"Schlechte","year":"2003","journal-title":"N Eng J Med"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1172\/JCI107421","article-title":"Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone","volume":"52","author":"Snyder","year":"1973","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000236081","article-title":"Prolactinoma in children and adolescents","volume":"72","author":"Fideleff","year":"2009","journal-title":"Horm Res"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1210\/jc.85.9.3053","article-title":"Primary medical therapy of micro- and macroprolactinomas in men","volume":"85","author":"Pinzone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4088\/JCP.v65n1205","article-title":"Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism","volume":"65","author":"Misra","year":"2004","journal-title":"J Clin Psych"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jcem-67-1-124","article-title":"Effects of prolactin and estrogen deficiency in amenorrhoeic bone loss","volume":"67","author":"Klibanski","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication induced hyperprolactinemia","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"Suppl","key":"10.1111\/j.1365-2362.2010.02399.x-BIB17|cit17","first-page":"39","article-title":"An evaluation of patients with hyperprolactinemia: have dynamic testings had their day?","volume":"7","author":"Di Sarno","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1210\/jc.80.8.2342","article-title":"Some forms of big big prolactine behave as complex of monomeric with an immunoglobulin G in patients with macroprolactinoma or prolactinomas","volume":"80","author":"Cavaco","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1530\/eje.0.1300434","article-title":"Effects of antiprolactin autoantibodies on serum prolactin measurements","volume":"130","author":"Hattori","year":"1994","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1365-2265.2002.01586.x","article-title":"Screening for macroprolactinemia and pituitary imaging studies","volume":"57","author":"Hauache","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF03347299","article-title":"Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect","volume":"21","author":"Petakov","year":"1998","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2265.1996.663486.x","article-title":"High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas","volume":"44","author":"St-Jean","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-2265.1997.1350956.x","article-title":"An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinemia","volume":"46","author":"Sawers","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0889-8529(05)70057-8","article-title":"Current approaches to imaging of the sellar region and pituitary","volume":"28","author":"Naidich","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB25|cit25","first-page":"175","article-title":"Development of hyperprolactinemia in patients with adenomas with and without prior operative treatment","volume":"584","author":"Von Werder","year":"1982","journal-title":"Excerpta Med Int Congress series"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0015-0282(16)59292-9","article-title":"The natural history of untreated microprolactinomas","volume":"48","author":"Sisam","year":"1987","journal-title":"Fertil Steril"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0002-9378(81)90553-6","article-title":"Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas","volume":"139","author":"March","year":"1981","journal-title":"Am J Obstet Gynecol"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the pituitary society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in patients with hyperprolactinemia","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertil Steril"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB30|cit30","first-page":"299","article-title":"Long-term follow-up of patients with untreated prolactin-secreting pituitary adenomas","volume":"45","author":"Jeffcoate","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis","volume":"68","author":"Schlechte","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinemia","volume":"54","author":"Karunakaran","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","article-title":"Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study","volume":"60","author":"Molitch","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumour shrinkage","volume":"13","author":"Bevan","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198608283150903","article-title":"Increase in bone mass after treatment of hyperprolactinemic amenorrhea","volume":"315","author":"Klibanski","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1210\/jc.83.3.807","article-title":"Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males","volume":"83","author":"Di Somma","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","article-title":"Pharmacologic resistance in prolactinoma patients","volume":"8","author":"Molitch","year":"2005","journal-title":"Pituitary"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jc.82.3.876","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1210\/jc.82.8.2756","article-title":"Prolactinoma apparently resistant to quinagolide respond to cabergoline therapy","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB41|cit41","first-page":"575","article-title":"The prolactinoma","volume":"23","author":"Colao","year":"2009","journal-title":"Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1210\/jc.81.6.2338","article-title":"Treatment of prolactin-secreting macroadenomas with the once weekly dopamine agonist cabergoline","volume":"81","author":"Biller","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF03348017","article-title":"Long-term treatment with cabergoline, a new long- lasting ergoline derivate, in idiopathic or tumourous hyperprolactinemia and outcome of drug-induced pregnancy","volume":"20","author":"Ciccarelli","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinoma","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/bmj.289.6452.1101","article-title":"Psychotic reactions during treatment of pituitary tumours with dopamine agonists","volume":"289","author":"Turner","year":"1984","journal-title":"Br Med J (Clin Res Ed)."},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8\u2003years of dopamine agonist therapy for prolactinoma","volume":"93","author":"Kars","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of triscupid regurgitationin patients with prolactinoma chronically treated with cabergoline","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/BF03345662","article-title":"Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies","volume":"31","author":"Bogazzi","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.2009-2095","article-title":"Potential cardiac valve effects of dopamine agonists in hyperprolactinemia","volume":"95","author":"Valassi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1210\/jc.85.6.2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","article-title":"Prolactinomas","volume":"362","author":"Klibanski","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1210\/jc.2009-0999","article-title":"Dopamine agonist therapy in prolactinomas: when can treatment be discontinued","volume":"94","author":"Klibanski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/1097-0142(19850715)56:2<230::AID-CNCR2820560204>3.0.CO;2-8","article-title":"Effects of bromocriptine on prolactin-secreting pituitary adenomas: mechanisms of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and mophometric analysis","volume":"56","author":"Mori","year":"1985","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1210\/jc.87.8.3578","article-title":"Long term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal","volume":"87","author":"Passos","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","article-title":"Predictors of remission of hyperprolactinemia after long-term withdrawal of cabergoline therapy","volume":"67","author":"Colao","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","article-title":"Recurrence of hyperprolactinemia following withdrawal of long-term cabergoline therapy","volume":"94","author":"Kharlip","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ncpendmet0968","article-title":"Pituitary apoplexy within a macroprolactinoma","volume":"4","author":"Watt","year":"2008","journal-title":"Nat Endocrinol Diab Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00006123-200201000-00007","article-title":"Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up","volume":"50","author":"Thomson","year":"2002","journal-title":"Neurosurgery"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1210\/jc.2003-030461","article-title":"Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume","volume":"88","author":"Barker","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB65|cit65","first-page":"108","article-title":"Prolactin excess: treatment and toxicity","volume":"2","author":"Gillam","year":"2004","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/jc.83.8.2777","article-title":"Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up","volume":"83","author":"Colao","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1530\/eje.0.1380286","article-title":"Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptin","volume":"138","author":"De Rosa","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198505233122106","article-title":"Pregnancy and the hyperprolactinemic woman","volume":"312","author":"Molitch","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2265.2007.03000.x","article-title":"Pregnancy outcomes following cabergoline treatment: extended results from a 12-year-observational study","volume":"68","author":"Colao","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1365-2362.2010.02399.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0028-2243(92)90094-F","article-title":"Long term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women","volume":"44","author":"Crosignani","year":"1992","journal-title":"Eur J Obs Gyn Rep Biol"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2010.02399.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2362.2010.02399.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T01:24:57Z","timestamp":1625361897000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2010.02399.x"}},"subtitle":["TREATMENT FOR PROLACTINOMAS AND HYPERPROLACTINAEMIA"],"short-title":[],"issued":{"date-parts":[[2010,10,18]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2010.02399.x","relation":{},"ISSN":["0014-2972"],"issn-type":[{"value":"0014-2972","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10,18]]}}}